Delivery of antibiotics to the respiratory tract: an update (Q37564542)

21 August 2017

1 reference

title

Delivery of antibiotics to the respiratory tract: an update (English)

1 reference

21 August 2017

Daniela Traini

1 reference

21 August 2017

Paul M Young

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Drug Delivery

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

897-905

1 reference

Fundamentals of pulmonary drug delivery.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Use of aerosolized antibiotics in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Ventilatory effects of aerosol gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Bronchoconstrictor additives in bronchodilator solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Aerosolized antibiotics for non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Quantitative deposition of aerosolized gentamicin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled vancomycin-induced allergic reaction in decontamination of respiratory tracts for allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Aerosol Polymyxin and Pneumonia in Seriously Ill Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled azithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Formulation of rifampicin-cyclodextrin complexes for lung nebulization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Propellant-driven metered-dose inhalers for pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Evidence for using nebulised antibiotics in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled micronised gentamicin powder: a new delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Cospray dried antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Microparticles for inhalational delivery of antipseudomonal antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

NanoCipro encapsulation in monodisperse large porous PLGA microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Antiinflammatory therapies for cystic fibrosis: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Development of spray dried liposomal dry powder inhaler of Dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903110710

10.1517/17425240903110710

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference